NCT03445533 2022-11-08A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory MelanomaIdera Pharmaceuticals, Inc.Phase 3 Terminated481 enrolled 22 charts
NCT01604889 2019-03-26A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaIncyte CorporationPhase 1/2 Terminated136 enrolled